Detalles de la búsqueda
1.
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Lancet Oncol
; 16(9): 1071-1078, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272768
2.
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Lancet Oncol
; 16(9): 1079-1089, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272769
3.
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Support Care Cancer
; 23(11): 3281-8, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25940030
4.
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial.
Lancet Rheumatol
; 5(8): e442-e450, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-38251576
Resultados
1 -
4
de 4
1
Próxima >
>>